Key publications
- Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019 Jan 30;11(477)
- van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, van der Schoot CE, IJspeert H, van der Burg M, Gils A, Hafkenscheid L, Toes REM, Rombouts Y, Plomp R, Wuhrer M, van Ham SM, Vidarsson G, Rispens T. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc Natl Acad Sci U S A. 2018; 115(8):1901-1906
- l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumabconcentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2017 211781.
- van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Ann Rheum Dis. 2017 Jul;76(7):1285-1288.
- Van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T. Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the antigen binding site. J Allergy Clin Immunol. 2017, 139:1035-1037
- Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Wolbink G, Rispens T. IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses. Arthritis Rheumatol. 2015 Dec;67(12):3124-34
- Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015,418, 29-38
- Van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ , Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann. Rheum. Dis. 2015, 74, 311-314
- Lighaam LC, Vermeulen E, Bleker Td, Meijlink KJ, Aalberse RC, Barnes E, Culver EL, van Ham SM, Rispens T. Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. J Allergy Clin Immunol. 2014 Jan;133(1):267-70.e1-6.
- Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC. Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc. 2011 Jul 6;133(26):10302-11
